Harvard Bioscience
HBIO
37 hedge funds and large institutions have $10.3M invested in Harvard Bioscience in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 16 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
34% more capital invested
Capital invested by funds: $7.73M → $10.3M (+$2.6M)
1.78% more ownership
Funds ownership: 35.46% → 37.24% (+1.8%)
0% more funds holding
Funds holding: 37 → 37 (0)
69% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Meros Investment Management
Dallas,
Texas
|
+$386K |
| 2 |
MBAM
Mink Brook Asset Management
West Palm Beach,
Florida
|
+$200K |
| 3 |
NCNMGF
Nano-Cap New Millennium Growth Fund
Staten Island,
New York
|
+$153K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$79.4K |
| 5 |
Goldman Sachs
New York
|
+$63.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$82.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$71.6K |
| 3 |
Jane Street
New York
|
-$59K |
| 4 |
WCM
Weber Capital Management
San Francisco,
California
|
-$55K |
| 5 |
WN
Williams & Novak
Westlake Village,
California
|
-$36.6K |
HBIO Hedge Fund Activity: Q2 2026 in Review
37 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q2 2026, worth a combined $10.3M — up 34% from $7.73M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new HBIO positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 16 trimmed.
The largest buyer was Meros Investment Management, adding an estimated $386K. The largest seller was Millennium Management, cutting an estimated $82.1K.
- 37 institutional investors held Harvard Bioscience (HBIO) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $10.3M of Harvard Bioscience stock for Q2 2026, up 34% quarter-over-quarter.
- 4 funds opened new Harvard Bioscience positions in Q2 2026 and 2 closed out, a net change of +2 holders.
- The largest Harvard Bioscience buyer in Q2 2026 was Meros Investment Management, an estimated $386K added.
- The largest Harvard Bioscience seller in Q2 2026 was Millennium Management, an estimated $82.1K sold.
Based on aggregated 13F filings for Q2 2026.